H. D. Hoving

Preclinical evaluation of a novel ¹¹¹In-labeled bombesin homodimer for improved imaging of GRPR-positive prostate cancer.

R. Dierckx, P. Elsinga, G. Carlucci, 2013, Molecular pharmaceutics.

Application of (99m)Technetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) SPECT/CT in prostate cancer patients: a first-in-man study.

S. Rosati, J. Pruim, Xiaoyuan Chen, 2013, Nuclear medicine and biology.

CXCR4 inhibition enhances radiosensitivity, while inducing cancer cell mobilization in a prostate cancer mouse model

S. Rosati, E. Vries, H. Timmer-Bosscha, 2014, Clinical & Experimental Metastasis.

Synthesis and Evaluation of F-Enzalutamide, a New Radioligand for PET Imaging of Androgen Receptors: A Comparison with 16b-F-Fluoro-5a-Dihydrotestosterone

R. Dierckx, E. Vries, P. Elsinga, 2021 .

Synthesis and Evaluation of 18F-Enzalutamide, a New Radioligand for PET Imaging of Androgen Receptors: A Comparison with 16β-18F-Fluoro-5α-Dihydrotestosterone

A. van Waarde, R. Dierckx, P. Elsinga, 2021, The Journal of Nuclear Medicine.

An update of radiolabeled bombesin analogs for gastrin-releasing peptide receptor targeting.

Fan Wang, R. Dierckx, P. Elsinga, 2013, Current pharmaceutical design.